{"filing":{"accession_number":"0001213900-26-093730","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-08-26","report_date":"2026-08-26","primary_document":"ea0303447-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026093730/ea0303447-6k_radiopharm.htm"},"events":[{"id":29629,"run_id":27144,"accession_number":"0001213900-26-093730","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This announcement discloses a material clinical milestone: dosing the first patient in the second cohort of a Phase 1/2a trial of RV-01, the company's lead radiopharmaceutical therapeutic developed through its joint venture with MD Anderson Cancer Center. The advancement to the 70 mCi dose level following a positive Safety and Monitoring Committee recommendation represents a significant operational and clinical progression for a clinical-stage biopharmaceutical company. While not a discrete event type like M\u0026A, exec change, or debt issuance, this clinical advancement is material to investors' assessment of the company's pipeline development and is best classified as an operational milestone.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-26","form":"6-K","submitted_at":null,"items":[{"id":31975,"accession_number":"0001213900-26-093730","item_number":"EX-99.1","item_title":"ea030344701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a material clinical milestone: dosing the first patient in the second cohort of a Phase 1/2a trial of RV-01, the company's lead radiopharmaceutical therapeutic developed through its joint venture with MD Anderson Cancer Center. The advancement to the 70 mCi dose level following a positive Safety and Monitoring Committee recommendation represents a significant operational and clinical progression for a clinical-stage biopharmaceutical company. While not a discrete event type like M\u0026A, exec change, or debt issuance, this clinical advancement is material to investors' assessment of the company's pipeline development and is best classified as an operational milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-26T12:01:20.695108+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31975,"accession_number":"0001213900-26-093730","item_number":"EX-99.1","item_title":"ea030344701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses a material clinical milestone: dosing the first patient in the second cohort of a Phase 1/2a trial of RV-01, the company's lead radiopharmaceutical therapeutic developed through its joint venture with MD Anderson Cancer Center. The advancement to the 70 mCi dose level following a positive Safety and Monitoring Committee recommendation represents a significant operational and clinical progression for a clinical-stage biopharmaceutical company. While not a discrete event type like M\u0026A, exec change, or debt issuance, this clinical advancement is material to investors' assessment of the company's pipeline development and is best classified as an operational milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-26T12:01:20.695108+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-08-26"}]}